Type 1 diabetes mellitus associated with pegylated interferon-α plus ribavirin treatment for chronic hepatitis C: Case report and literature review

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 4, Issue , 2011, Pages 39-45

  Oka, Reiko ^a,b   Hiroi, Naoki ^b   Shigemitsu, Rika ^a,b   Sue, Mariko ^b   Oshima, Yasuo ^a   Yoshida Hiroi, Mayumi ^a  

^a Social Insurance Central Hospital   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis C; Pegylated interferon; Ribavirin; Type 1 diabetes mellitus

Indexed keywords

GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; GLYCOSYLATED ALBUMIN; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; CASE REPORT; DOSE RESPONSE; DRUG DOSE REDUCTION; ERYTHROCYTE COUNT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; MICROALBUMINURIA; PHYSICAL EXAMINATION; POLYDIPSIA; POLYURIA; PROTEIN BLOOD LEVEL; REVIEW; THIRST; TREATMENT DURATION;

EID: 80053618490     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S7815     Document Type: Review

References (30)

1. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther. 2003;18:549-8.
2. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology. 2011;53:32-41.
3. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet. 1992; 340:548.
4. NIH Consensus Statement on Management of Hepatitis C, 2002. Available from:http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm. Accessed July 30, 2011.
5. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol. 2008;82:2606-12.
6. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592-9.
7. Chen LK, Chou YC, Tsai ST, Hwang SJ, Lee SD. Hepatitis C virus infection-related Type 1 diabetes mellitus. Diabet Med. 2005;22:340-3.
8. Shiba T, Morino Y, Tagawa K, Fujino H, Unuma T. Onset of diabetes with high titer anti-glutamic acid decarboxylase antibody after IFN therapy for chronic hepatitis. Diabetes Res Clin Pract. 1995;30:237-41.
9. Fabris P, Betterle C, Greggio NA, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol. 1998; 28:514-7.
10. Uto H, Matsuoka H, Murata M, et al. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy. Diabetes Res Clin Pract. 2000;49: 101-6.
11. Recasens M, Aguilera E, Ampurdanés S, et al. Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C. Diabet Med. 2001;18:764-7.
12. Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: A case of Th1-mediated disease? Diabet Med. 2001;18:329-32.
13. Eibl N, Gschwantler M, Ferenci P, Eibl MM, Weiss W, Schernthaner G. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha. Eur J Gastroenterol Hepatol. 2001;13:295-8.
14. Bhatti A, McGarrity TJ, Gabbay R. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C. Am J Gastroenterol. 2001;96:604-5.
15. Mofredj A, Howaizi M, Grasset D, et al. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci. 2002;47:1649-54.
16. Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2006;18:689-92.
17. Tosone G, Borgia G, Gentile I, et al. A case of pegylated interferon alpharelated diabetic ketoacidosis: Can this complication be avoided? Acta Diabetol. 2007;44:167-9.
18. Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol. 2007;13:1292-4.
19. Schreuder TC, Gelderblom HC, Weegink CJ, et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int. 2008;28:39-46.
20. Tanaka J, Sugimoto K, Shiraki K, et al. Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Intern Med. 2008;47:747-9.
21. Nakamura K, Kawasaki E, Abiru N, et al. Trajectories of anti-islet autoantibodies before development of type 1 diabetes in interferon-treated hepatitis C patients. Case reports and a literature review. Endocr J. 2010;57:947-51.
22. Ogihara T, Katagiri H, Yamada T, et al. Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C. Intern Med. 2009;48:1387-90.
23. Yamazaki M, Sato A, Takeda T, Komatsu M. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Intern Med. 2010;49:403-7.
24. Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Res Clin Pract. 2009;86:e19-21.
25. Fujioka T, Honda M, Yoshizaki T, et al. A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-alpha plus ribavirin treatment for chronic hepatitis C. Intern Med. 2010;49:1987-90.
26. Farrar DJ, Murphy KM. Type I interferons and T helper development. Immunol Today. 2000;21:484-9.
27. Tilg H. New insights into the mechanisms of interferon alfa: An immunoregulatory and anti-inflammatory cytokine. Gastroenterology. 1997;112:1017-21.
28. Yamada K, Otabe S, Inada C, Takane N, Nonaka K. Nitric oxide and nitric oxide synthase mRNA induction in mouse islet cells by interferon-gamma plus tumor necrosis factor-alpha. Biochem Biophys Res Commun. 1993;197:22-7.
29. Yamada K, Takane-Gyotoku N, Yuan X, Ichikawa F, Inada C, Nonaka K. Mouse islet cell lysis mediated by interleukin-1-induced F. Diabetologia. 1996;39:1306-12.
30. Furusyo N, Kubo N, Toyoda K, et al. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. Antiviral Res. 2005;67:46-54.